{"schema_version":"secwatch.filing_event.v1","accession":"0001679363-24-000029","form_type":"8-K","ticker":null,"cik":"0001679363","company_name":"Morphic Holding, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.548074+00:00","generated_at":"2026-06-03T08:05:16.856892+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Morphic Q1 net loss $45.3M ($0.91/sh); EMERALD-2 enrollment on track; CMO appointed","bullets":["Net loss of $45.3M ($0.91/sh) vs. $36.1M ($0.90/sh) in Q1 2023; R&D expense $42.4M (up 39%).","Cash, equivalents, and marketable securities $658.8M; cash runway into H2 2027.","EMERALD-2 Phase 2b trial in UC enrollment on track; primary endpoint readout expected H1 2025.","First patient dosing in GARNET Phase 2 Crohn's study expected Q2 2024.","Appointed Dr. Simon Cooper as CMO; he previously developed risankizumab at AbbVie for UC and CD."],"urls":{"canonical":"https://secwatch.observer/filing/0001679363-24-000029","json":"https://secwatch.observer/filing/0001679363-24-000029.json","markdown":"https://secwatch.observer/filing/0001679363-24-000029.md","text":"https://secwatch.observer/filing/0001679363-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/0001679363-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/morf-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:05:16.856892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f905b0b9ed0474482f15fc4e8b4340606755c801","claim":"Morphic Holding, Inc. reported the first quarter 2024 results: net income Net loss for the quarter ended March 31, 2024, was $45.3 million or $0.91 per share, EPS $0.91 per share.","evidence_excerpt":"Net loss for the quarter ended March 31, 2024, was $45.3 million or $0.91 per share compared to net loss of $36.1 million or $0.90 per share for the same quarter last year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/0001679363-24-000029-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2024"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2024, was $45.3 million or $0.91 per share"},{"label":"EPS","value":"$0.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}